Associations of Early Pregnancy and Neonatal Circulating Folate, Vitamin B-12, and Homocysteine Concentrations with Cardiometabolic Risk Factors in Children at 10 y of Age

Giulietta S Monasso,1,2 Susana Santos,1,2 Madelon L Geurtsen,1,2 Sandra G Heil,3 Janine F Felix,1,2 and Vincent WV Jaddoe1,2

1The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; 2Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; and 3Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

ABSTRACT

Background: Higher circulating folate and vitamin B-12 concentrations and lower circulating homocysteine concentrations during pregnancy seem to be associated with fetal development. These micronutrients may also be associated with cardiometabolic health.

Objective: We examined the associations of circulating folate, vitamin B-12, and homocysteine concentrations during pregnancy and in neonates with childhood cardiometabolic outcomes.

Methods: This study was embedded in the Generation R Study, a population-based prospective cohort study from early pregnancy onward. We sampled blood in early pregnancy and cord blood. We measured cardiometabolic outcomes in the children at school age. Among 4449 children aged 10 y (median: 9.7; 95% range: 9.3, 10.7), we examined associations of plasma folate, serum vitamin B-12, and plasma homocysteine concentrations in early pregnancy and at birth with BMI, body fat distribution, heart rate, blood pressure, and insulin, glucose, and lipid concentrations, using linear regression models. Using logistic models, we examined the associations of these micronutrients with risks of overweight/obesity and clustering of cardiovascular risk factors.

Results: One standard deviation score (SDS) higher maternal plasma folate concentration was associated with lower BMI (−0.04 SDS; 95% CI: −0.08, −0.01), android-to-gynoid fat ratio (−0.06 SDS; 95% CI: −0.13, −0.00), systolic blood pressure (−0.06 SDS; 95% CI: −0.10, −0.03), risk of overweight (OR: 0.87; 95% CI: 0.78, 0.96), and clustering of cardiovascular risk factors (OR: 0.79; 95% CI: 0.68, 0.91). One SDS higher maternal serum total B-12 concentration was associated with lower glucose (−0.06 SDS; 95% CI: −0.10, −0.02) and higher HDL cholesterol concentrations (0.04 SDS; 95% CI: 0.00, 0.08). Cord blood folate, vitamin B-12, and homocysteine concentrations were not consistently associated with cardiometabolic outcomes.

Conclusions: Subtle differences in circulating folate and vitamin B-12 concentrations in early pregnancy may be associated with child cardiometabolic health at age 10 y. The causality and mechanisms underlying these associations need further study.

Keywords: folate, vitamin B-12, holotranscobalamin, homocysteine, cardiovascular health, cohort, childhood

Introduction

An adverse maternal nutritional status during pregnancy may have long-term consequences for offspring cardiometabolic health (1). Folate, vitamin B-12, and homocysteine interact in 1-carbon metabolism and are crucial for cellular growth and differentiation, nucleic acid synthesis, and DNA methylation (2–5). Without supplementation, circulating folate, vitamin B-12, and homocysteine concentrations decline during pregnancy due to increased demand for fetal growth, hormonal changes, and hemodilution (6–9). Periconceptional folic acid supplementation is advised as standard prenatal care (10). Circulating folate or vitamin B-12 deficiency may result in

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Manuscript received November 3, 2020. Initial review completed December 3, 2020. Revision accepted February 2, 2021.
First published online March 23, 2021; doi: https://doi.org/10.1093/jn/nxab039.
elevated circulating homocysteine concentrations (5, 11, 12). In adults, hyperhomocysteinemia is associated with endothelial dysfunction and increased cardiovascular risk (13–15). Previous prospective birth cohorts, including the cohort in which the current study was embedded, have suggested associations of not taking folic acid supplements and of suboptimal maternal folate, vitamin B-12, and homocysteine blood concentrations in pregnancy with lower uteroplacental vascular resistance, lower offspring birth weight, higher BMI, higher heart rate, and lower kidney function in offspring at school age (4, 16–21). No previous studies have assessed associations of multiple 1-carbon metabolism markers, measured at 2 time points in pregnancy, with a wide range of detailed cardiometabolic outcomes in childhood. Also, an imbalance between circulating maternal high folate and low vitamin B-12 blood concentrations may be associated with more adverse health outcomes in the children, but research on this topic is limited (12, 22). Active B-12, or holotranscobalamin, is the biologically active fraction of vitamin B-12 and possibly is a more reliable marker of an impaired vitamin B-12 status in pregnancy (5). Associations of active B-12 concentrations in pregnancy with cardiometabolic health in childhood were not studied previously. Based on the findings of previous studies, we hypothesized that higher circulating folate and vitamin B-12 concentrations, as well as lower circulating homocysteine concentrations, are associated with better fetal development and subsequently cardiometabolic outcomes in childhood. In a population-based study among 4449 mother–child pairs, we examined associations of plasma folate, serum total and active B-12, and plasma homocysteine concentrations in early pregnancy and in cord blood with BMI, body fat distribution, heart rate, blood pressure, and insulin, glucose, and lipid concentrations in the children at age 10 y. We explored whether imbalanced maternal circulating folate and vitamin B-12 status was associated with these outcomes. Also, we assessed associations of circulating 1-carbon metabolism markers with risks of overweight and clustering of cardiovascular risk factors in childhood.

Methods

Participants

This study was embedded in the Generation R Study, a population-based prospective cohort study from fetal life onward in Rotterdam, the Netherlands (23). It was designed to identify early environmental and genetic causes of normal and abnormal growth, development, and health (23). Pregnant women with an expected delivery date between April 2002 and January 2006 living in Rotterdam were eligible to participate. Enrollment was aimed at early pregnancy but was allowed until the birth of the child. The Medical Ethical Committee of the Erasmus University Medical Center in Rotterdam approved the study (MEC 198.782/2001/31). Written informed consent was obtained from all participants. Data collection included blood sampling in pregnancy and in cord blood (23). Also, we measured cardiometabolic outcomes in the children at 10 y. In the current study, we included 4449 singleton multietnic children aged 10 (median: 9.7; 95% range: 9.3, 10.7) years with at least 1 measurement of circulating folate, total or active B-12, or homocysteine concentrations in either pregnancy or in cord blood and 1 or more cardiometabolic risk factors measured. A flowchart of the study population is shown in Supplemental Figure 1.

Folate, vitamin B-12, and homocysteine concentrations

As described previously, maternal venous blood samples were drawn in early pregnancy (median weeks of gestation, 13.2; IQR: 12.2–14.8 wk), and cord blood samples were taken immediately after delivery by midwives (40.1; IQR: 39.3–41.0 wk of gestation) (18). Blood samples were stored at room temperature for a maximum of 3 h before being transported to the regional laboratory for processing and storage at −80°C. After thawing, EDTA plasma folate and homocysteine concentrations and serum total and active B-12 concentrations were analyzed in the Department of Clinical Chemistry at the Erasmus University Medical Centre, Rotterdam, using an immune-electrochemiluminescence assay on the Architect System (18). Active B-12 was analyzed in stored serum samples only and therefore available in a smaller subgroup. We also dichotomized maternal and cord blood folate (≥8 and <8 nmol/L, respectively), total B-12 (≥145 and <145 pmol/L, respectively), active B-12 (≥21 and <21 pmol/L, respectively), and homocysteine (<19 and ≥19 μmol/L, respectively) concentrations into normal and low according to the 95% reference interval for healthy adults (4, 6, 24, 25). To explore whether an imbalance of circulating maternal high folate status and low vitamin B-12 status is associated with detrimental cardiometabolic outcomes in childhood (12, 22), we categorized mothers based on their combined circulating folate/total B-12 status and similarly based on their combined circulating folate/active B-12 status. Plasma folate concentrations in the first/second tertile (<22.6) were defined as “low/normal”; concentrations in the third tertile (≥22.6 nmol/L) were defined as “high.” Serum total B-12 was again dichotomized based on the 95% reference interval, as values <145 pmol/L corresponded to the first tertile. Serum active B-12 concentrations in the first tertile (<36 pmol/L) were defined as “low” and concentrations in the second/third tertile as “normal/high.” Groups to analyze any circulating folate/total B-12 imbalance were low/normal folate + normal/high total B-12 (reference), high folate + normal/high total B-12, low/normal folate + low total B-12, and high folate + low total B-12. Similarly, we grouped mothers into circulating low/normal folate + normal/high active B-12 (reference), high folate + normal/high active B-12, low/normal folate + low active B-12, and high folate + low active B-12. Periconceptional folic acid supplementation was assessed by questionnaires. We categorized mothers into no supplementation, started before 10 wk gestational age, and started preconception (reference).

Childhood fat and cardiometabolic measurements

When children visited the research facility at age 10 y, we calculated BMI (in kg/m²) from weight and height and subsequently sex- and age-adjusted standard deviation scores (SDSs), based on Dutch reference growth charts (Growth Analyzer 4.0; Dutch Growth Research Foundation) (26). We categorized BMI into underweight, normal weight, and overweight/obesity, based on the International Obesity Task Force cutoffs (27). We measured children’s body composition with a DXA scanner (iDXA; GE-Lunar 2008, Madison, WI, USA) using enCORE software version 12.6 (28). From these measurements, of which details have been described previously, we calculated fat mass index [FMI, fat mass (kg)/height (m²)] and android fat mass as a...
percentage of total fat mass (29). We calculated the ratio of android and gynoid fat mass, which reflects the relation between fat mass in the abdominal (android) and hip (gynoid) regions. We assessed heart rate and blood pressure at the right brachial artery 4 times with 1-min intervals with the validated automatic sphygmomanometer Datascope Accutorr Plus (Paramus, NJ, USA) (30). Mean heart rate and systolic and diastolic blood pressure were calculated from the last 3 measurements. We obtained venous blood samples after 30 min of fasting and measured insulin, glucose, total cholesterol, HDL cholesterol, and triglyceride concentrations (23). We measured insulin concentrations with the electro-chemiluminescence immunoassay on the E411 module (Roche) and glucose, total and HDL cholesterol, and triglyceride concentrations with the c702 module on the Cobas 8000 analyzer. We calculated LDL cholesterol concentrations using the Friedewald formula (31). As previously, we defined clustering of cardiovascular risk factors as having at least 3 of the following 4 risk factors: android fat mass percentage >75th percentile, systolic or diastolic blood pressure or both >75th percentile, HDL cholesterol <25th percentile or triglycerides >75th percentile or both, and insulin concentration >75th percentile of our study population (32, 33).

Covariates
We selected potential covariates based on previous literature and constructed a directed acyclic diagram (Supplemental Figure 2). From questionnaires sent out in each trimester of pregnancy, we obtained information on maternal age, highest completed education according to the classification of Statistics Netherlands as a proxy for socioeconomic status, prepregnancy BMI, parity, and smoking and alcohol consumption during pregnancy (23, 34). From questionnaires and midwife and hospital records, we obtained information on gestational age at blood sampling, sex, child ethnicity according to European reference chart (35, 36).

Statistical analysis
First, we performed a nonresponse analysis by comparing child characteristics with and without at least 1 outcome measurement using Student t tests, Mann–Whitney tests, and χ² tests. Second, we examined the associations of circulating folate, total and active B-12, and homocysteine concentrations with all outcomes using multivariable linear regression models. Basic models were adjusted for sex, child age, and gestational age at blood sampling. Main models were also adjusted for maternal age, education, prepregnancy BMI, smoking and alcohol consumption, parity, and child ethnicity. To compare effect estimates, exposures and outcomes were analyzed in SDSs after natural log transformation of FMI, android fat mass percentage, android-to-gynoid fat ratio, and insulin and triglyceride concentrations, which all had skewed distributions (4, 33). As a sensitivity analysis, we assessed whether effect estimates of the associations were similar in an ethnic homogeneous Dutch subgroup. Also, we explored associations of folic acid supplementation and of dichotomized maternal circulating early pregnancy folate concentrations with all outcomes. Similar analyses were performed to explore associations of potentially imbalanced maternal circulating folate/vitamin B-12 status with childhood blood pressure (−0.06 SDS; 95% CI: −0.10, −0.03). Also, compared with taking no supplementation, starting folic acid preconception was associated with lower childhood systolic blood pressure (−0.17 SDS; 95% CI: −0.28, −0.06), FMI (−0.27 SDS; 95% CI: −0.37, −0.17), fat mass percentage (−0.23 SDS; 95% CI: −0.33, −0.12), and android-to-gynoid fat ratio (−0.24 SDS; 95% CI: −0.35, −0.14). Active B-12, total B-12, and homocysteine blood concentrations were not associated with childhood fat measurements. The results from basic models were largely similar (data not shown). Mediator models are shown in Supplemental Table 5. We observed no evidence for associations of maternal imbalanced circulating folate/vitamin B-12 status with childhood fat measurements (Supplemental Table 6).

Childhood cardiometabolic measurements
Table 4 shows that 1 SDS (9.1 nmol/L) higher maternal plasma folate concentrations were associated with lower childhood systolic blood pressure (−0.06 SDS; 95% CI: −0.10, −0.03). Also, compared with taking no supplementation, starting folic acid preconception was associated with lower childhood systolic blood pressure (−0.19 SDS; 95% CI: −0.30, −0.08). One SDS (93 pmol/L) higher serum total B-12 concentrations in early pregnancy were associated with lower glucose concentrations (−0.06 SDS; 95% CI: −0.10, −0.02) and higher HDL cholesterol concentrations (0.04 SDS; 95% CI: 0.00, 0.08) in childhood, whereas 1 SDS (20 pmol/L) higher serum active B-12 concentrations were associated with lower childhood diastolic blood pressure (−0.05 SDS, 95% CI: −0.09, −0.01). Models with dichotomized circulating early pregnancy folate and total B-12 concentrations showed consistent results (Table 4). In neonates, 1 SDS (29 pmol/L) higher serum active B-12 concentrations were associated with lower childhood heart rates (−0.04 SDS; 95% CI: −0.08, −0.01) and glucose concentrations (−0.05 SDS; 95% CI: −0.10, −0.01) but higher HDL cholesterol concentrations (0.05 SDS; 95% CI: 0.00, 0.09). For heart rate and glucose, these associations had similar effect estimates but attenuated into nonsignificance after adjustment for plasma homocysteine (Supplemental Table 7). One SDS (2.9 μmol/L) higher cord blood homocysteine concentrations were associated with higher childhood...
TABLE 1 Characteristics of participating mother–child pairs (n = 4449)

| Characteristic | Value |
|----------------|-------|
| Maternal characteristics | |
| Age, y | 30.7 (4.8) |
| Educational level | |
| No or primary | |
| Secondary | 1777 (41.9) |
| Higher | 2158 (50.8) |
| Parity | |
| Nulliparous | 2610 (59.0) |
| Multiparous | 1817 (41.0) |
| Prepregnancy BMI, kg/m² | 22.6 (18.1, 34.3) |
| Smoking | |
| Nonsmoker or smoked until pregnancy was known | 3377 (84.3) |
| Smoked throughout pregnancy | 629 (15.7) |
| Alcohol consumption | |
| Nonuser or consumption until pregnancy was known | 2234 (56.5) |
| Sustained consumption | 1722 (43.5) |
| Gestational age at blood sampling, wk | 13.2 (9.8, 17.4) |
| Newborn characteristics | |
| Gestational age, wk | 40.1 (36.0, 42.3) |
| Birth weight, kg | 3.47 (2.28, 4.46) |
| Sex | |
| Boy | 2196 (49.4) |
| Girl | 2253 (50.6) |
| Ethnicity | |
| European | 3005 (68.5) |
| Non-European | 1380 (31.5) |
| Childhood characteristics | |
| Child age at visit, y | 9.7 (9.3, 10.7) |
| Childhood BMI, kg/m² | 17.6 (2.8) |
| Underweight | |
| Normal weight | |
| Overweight | 632 (14.2) |
| Obese | 158 (3.6) |
| Fat mass index, kg/m² | 2.2 (1.2, 5.0) |
| Android fat mass, % | 4.0 (2.4, 7.7) |
| Android-to-gynoid fat ratio | 0.24 (0.15, 0.49) |
| Heart rate, beats per minute | 73.4 (9.8) |
| Blood pressure, mmHg | |
| Systolic | 103 (7.9) |
| Diastolic | 59 (6.4) |
| Insulin, pmol/L | 175 (216, 636) |
| Glucose, mmol/L | 5.2 (0.9) |
| Total cholesterol, mmol/L | 4.3 (0.7) |
| HDL cholesterol, mmol/L | 1.5 (0.3) |
| LDL cholesterol, mmol/L | 2.3 (0.6) |
| Triglycerides, mmol/L | 1.0 (0.4, 2.8) |
| Prevalence cardiovascular clustering, n (%) | 391 (13.3) |

Values are based on nonimputed data and are mean (SD) or median (95% range) for continuous variables and numbers (%) for categorical variables.

2 Standard deviation scores were calculated for these variables.

3 Indicate values before natural log transformation.

4 Underweight, normal weight, overweight, and obesity were defined based on the International Obesity Task Force cutoffs (sex and age specific), defined to pass through a BMI of 25 and 30 kg/m² at age 18 y (27).

5 Cardiovascular clustering was defined as having 3 or more risk factors (android fat mass >75th percentile, systolic or diastolic blood pressure >75th percentile or both, HDL cholesterol <25th percentile or triglycerides >75th percentile or both, insulin concentration >75th percentile of our study population). The prevalence of cardiovascular clustering was calculated in the subgroup of n = 4401 children with complete cardiovascular outcomes.

64 Underweight, normal weight, overweight, and obesity were defined based on the International Obesity Task Force cutoffs (sex and age specific), defined to pass through a BMI of 25 and 30 kg/m² at age 18 y (27).

Discussion

Our results suggest that higher maternal plasma folate concentrations in early pregnancy are associated with lower BMI and FMI in children at age 10 y and with lower risk of overweight and clustering of cardiometabolic outcomes. We found some evidence that optimal circulating folate, vitamin B-12, and homocysteine concentrations during fetal development are associated with individual favorable cardiometabolic outcomes in childhood. An imbalance between circulating maternal high folate and low total B-12 was associated with higher childhood glucose concentrations.

An adverse nutritional status during fetal life may contribute to development of disease in later life (1). Folate and vitamin B-12 are essential for cellular growth and differentiation and regulate homocysteine metabolism (6, 12). Higher circulating folate and vitamin B-12 concentrations and lower homocysteine concentrations during pregnancy may be associated with more favorable cardiometabolic outcomes in childhood.

We observed that higher maternal plasma folate concentrations in early pregnancy were associated with lower BMI and FMI, as well as lower risk of overweight in the children at age 10 y. Periconceptional folic acid supplementation was associated with a favorable body fat distribution in childhood. Five smaller previous studies, embedded in prospective birth cohort studies, have examined associations of any 1-carbon metabolism markers with body fat measurements but are less comprehensive compared with our study (16, 17, 22, 38, 39). Of these, 3 Western studies assessed BMI only in younger children (16, 17, 38). The first, among 1950 multietnic children from Amsterdam, reported associations of higher early pregnancy folate concentrations with lower BMI at age 5 y. This association was similar among Dutch children only. The second study included 1517 six-year-old children from low-income families in Boston and suggested a higher risk of overweight among children of mothers with postpartum circulating folate concentrations in the lowest quartile compared with higher quartiles. In our study population, high folic acid intakes as toddlers were associated with lower body weight and BMI...
(n = 2922) at age 6 y (38). Only 2 small Indian studies examined associations of 1-carbon metabolism markers with body fat distribution (22, 39). One study among 674 children aged 6 y observed positive associations between folate concentrations in pregnancy and fat mass and fat mass percentage but not lean mass (22). These associations of higher folate concentrations with unfavorable body fat distribution may be explained by differences in socioeconomic status and diet (16, 22, 39). The second study, among 478 children, found no associations of folate concentrations in pregnancy with skinfold or fat mass percentage at 3 ages (39). In our relatively large study population, we were able to confirm absence of associations between circulating vitamin B-12 concentrations in pregnancy and diastolic blood pressure at age 6 y, which was no longer significant in the full model. No information on homocysteine concentrations was available (16). A second study, embedded in the Boston cohort, examined maternal postpartum folate blood concentrations in 492 mothers with a cardiometabolic risk factor and found that concentrations above the median were associated with a lower risk of elevated systolic blood pressure in their children aged 6 y (41). A third study among 2863 children, embedded in our cohort, reported that higher maternal early pregnancy total B-12 but not folate and homocysteine concentrations were associated with higher diastolic blood pressure at age 6 y (21). A similar unexpected inverse association has been reported between vitamin B-12 and birth weight and could be explained by reverse causation, as smaller fetuses require less vitamin B-12 for development (18). To our knowledge, we are the first reporting on associations of higher cord blood active B-12 concentrations with lower childhood heart rates and glucose concentrations but higher HDL cholesterol concentrations. Also, higher cord blood homocysteine concentrations were positively associated with childhood insulin and glucose concentrations. One of the studies from India observed positive associations between homocysteine concentrations in late pregnancy and glucose concentrations in children aged 5 and 10 y (39). The differences

| Characteristic | Maternal early pregnancy (n = 3701) | Cord blood (n = 3112) |
|---------------|----------------------------------|-----------------------|
| Plasma folate concentration, nmol/L | 17.4 (6.0, 38.0) | 20.8 (10.6, 38.5) |
| 1 SDS, nmol/L | 9.1 | 7.6 |
| ≥8 nmol/L | 3254 (89.6) | 3014 (99.8) |
| <8 nmol/L | 378 (10.4) | 7 (0.2) |
| Serum total B-12 concentration, pmol/L | 172 (76, 414) | 303 (120, 903) |
| 1 SDS, pmol/L | 93 | 202 |
| ≥145 pmol/L | 2301 (66.3) | 2877 (94.2) |
| <145 pmol/L | 1170 (33.7) | 178 (5.8) |
| Serum active B-12 concentration, pmol/L | 42 (18, 98) | 87 (36, 128) |
| 1 SDS, pmol/L | 20 | 29 |
| ≥21 pmol/L | 2478 (95.5) | 2909 (99.8) |
| <21 pmol/L | 118 (4.5) | 7 (0.2) |
| Plasma homocysteine concentration, μmol/L | 6.9 (4.6, 11.6) | 9.0 (7.4, 16.2) |
| 1 SDS, μmol/L | 2.0 | 2.9 |
| <19 μmol/L | 3583 (99.6) | 2905 (99.1) |
| ≥19 μmol/L | 13 (0.4) | 25 (0.9) |
| Folic acid supplement use | No | — |
| From early pregnancy | 550 (19.0) | — |
| Yes, from preconception | 937 (32.4) | — |
| Yes, from preconception | 1406 (48.6) | — |

1 Values are based on nonimputed data and are median (95% range) for continuous variables and numbers (%) for categorical variables. SDS, standard deviation score.

2 Folate, vitamin B-12, and homocysteine were dichotomized based on the 95% reference interval for healthy adults.

3 Information on folic acid supplement use was available in 2893 mothers with information on maternal folate concentration in early pregnancy.
TABLE 3 Associations of circulating folate, vitamin B-12, and homocysteine concentrations in early pregnancy and in cord blood with body fat measurements in children aged 10 years

| Characteristic | Body mass index (n = 4438) | Fat mass index (n = 4401) | Android fat mass, % (n = 4401) | Android-to-gynoid fat ratio (n = 4401) |
|---------------|-----------------------------|---------------------------|-------------------------------|-------------------------------------|
| Maternal early pregnancy | | | | |
| Folate, SDS ≥8 nmol/L | −0.04 (−0.08, −0.01)* | −0.04 (−0.07, −0.01)* | −0.02 (−0.05, 0.01) | −0.03 (−0.06, 0.01) |
| Folate, SDS <8 nmol/L | 0.15 (0.05, 0.26)* | 0.16 (0.07, 0.26)** | 0.14 (0.03, 0.24)** | 0.16 (0.00, 0.03)* |
| Total B-12, SDS ≥145 pmol/L | 0.02 (−0.02, 0.05) | −0.00 (−0.03, 0.03) | −0.02 (−0.05, 0.01) | −0.02 (−0.05, 0.01) |
| Total B-12, SDS <145 pmol/L | 0.00 (−0.07, 0.07) | 0.02 (−0.04, 0.08) | 0.05 (−0.02, 0.12) | 0.04 (−0.03, 0.11) |
| Active B-12, SDS | 0.03 (−0.01, 0.07) | 0.00 (−0.03, 0.04) | −0.03 (−0.07, 0.01) | −0.02 (−0.05, 0.02) |
| Homocysteine, SDS | −0.00 (−0.03, 0.03) | −0.01 (−0.04, 0.02) | 0.02 (−0.01, 0.05) | 0.02 (−0.01, 0.05) |

Folic acid supplement use | | | | |
| No | | | | |
| From early pregnancy | −0.05 (−0.16, 0.06) | −0.11 (−0.21, −0.01)* | −0.10 (−0.20, 0.01) | −0.12 (−0.23, −0.02)* |
| From preconception | −0.17 (−0.28, −0.06)** | −0.27 (−0.37, −0.17)** | −0.23 (−0.33, −0.12)** | −0.24 (−0.35, −0.14)** |

Cord blood | | | | |
| Folate, SDS | −0.01 (−0.04, 0.03) | −0.00 (−0.04, 0.03) | 0.01 (−0.03, 0.04) | 0.01 (−0.02, 0.05) |
| Total B-12, SDS | 0.01 (−0.03, 0.04) | 0.01 (−0.02, 0.05) | −0.01 (−0.04, 0.02) | −0.01 (−0.04, 0.03) |
| Active B-12, SDS | 0.02 (−0.01, 0.06) | 0.02 (−0.02, 0.05) | −0.00 (−0.04, 0.03) | 0.00 (−0.03, 0.04) |
| Homocysteine, SDS | −0.01 (−0.04, 0.03) | −0.02 (−0.05, 0.02) | −0.01 (−0.04, 0.03) | −0.01 (−0.04, 0.03) |

1The main models were adjusted for child sex, gestational age at blood sampling, child age at outcome, maternal confounders (parity, age, education, prepregnancy BMI, smoking, alcohol consumption), and child ethnicity. Folate and homocysteine were measured in plasma and total and active B-12 were measured in serum. *P < 0.05. **P < 0.01. 3% SDS, standard deviation score.
2For early pregnancy active B-12 and homocysteine, and cord blood folate, total and active B-12 and homocysteine, the distribution of participants after dichotomization was deemed too uneven for meaningful analyses.
3Plasma folate ≥8 nmol/L: n = 3254; plasma folate <8 nmol/L: n = 378.
4Serum total B-12 ≥145 pmol/L: n = 2301; serum total B-12 <145 pmol/L: n = 1170.

in our study for early pregnancy and cord blood may possibly be explained by changes in maternal metabolism during pregnancy (42).

In the most thorough analysis so far, we observed an association of imbalanced maternal circulating high folate and low vitamin B-12 status with higher offspring glucose concentrations. One Indian study reported that offspring of mothers with such an imbalance were more insulin resistant (22). An underlying mechanism for these associations could be that high folic acid intake (e.g., via supplements) prevents the acceptance of the methyl group from 5-methyl tetrahydrofolate and dysregulates 1-carbon metabolism by oxidizing the cobalt of vitamin B-12 (12). This association needs further replication.

The mechanisms underlying the observed associations may include epigenetic fetal reprogramming in response to an adverse environment in utero (1). The 1-carbon metabolism is essential for DNA methylation (6). Folate and vitamin B-12 are important for fetal growth and development. Accelerated postnatal growth to compensate for fetal growth restriction is associated with cardiometabolic disease in later life (18). Suboptimal vitamin B-12 status may affect fetal neurodevelopment and autonomic regulation, potentially influencing blood pressure and heart rate (16). High homocysteine concentrations have been associated with endothelial dysfunction and increased cardiovascular risk in adults but also with preeclampsia, prematurity, and low birth weight (3, 4, 13, 18). In pregnancy, active B-12 seems critical as greater amounts of total B-12 are partitioned toward active B-12 (6). This could explain why we observed more associations for active compared with total B-12.

Although effect estimates were small, our findings emphasize that even minor fluctuations in circulating folate, vitamin B-12, and homocysteine concentrations during fetal development may be associated with childhood cardiometabolic health. This is relevant, as childhood health may contribute to health in adult life. Strengths of this study are its implementation in an observational cohort study, large sample size, active B-12 measurements, and availability of detailed cardiometabolic outcomes. After sampling, blood was stored at room temperature for up to 3 h. Time-dependent increases in plasma homocysteine concentrations, due to continued production and release of homocysteine from blood cells, may have limited our capacity to detect associations between plasma homocysteine concentrations and all outcomes (43). Although we excluded few children, the nonresponse analysis suggested that they were from a lower socioeconomic background, and selection bias could have led to underestimation of our results. We measured plasma glucose and insulin in nonfasting samples. This may have led to misclassification, although this seems no bias could have led to underestimation of our results. We performed many statistical tests but did not adjust for multiple testing, as exposures and outcomes were correlated. We adjusted for potential confounders but cannot exclude residual confounding due to unmeasured factors. After dichotomization based on the 95% reference ranges, only maternal circulating folate and total B-12 concentrations were evenly distributed for meaningful analyses. Using lower cutoffs (e.g., 12–15 μmol/L as used in previous studies for elevated blood homocysteine concentrations) was not possible due to low numbers (45–47). Similarly, our analyses on the associations of imbalanced maternal circulating folate and vitamin B-12 status were limited by the distribution of plasma folate concentrations in our cohort. Few mothers had extreme plasma folate concentrations, corresponding to the upper limit of the 95% reference range.
**TABLE 4** Associations of circulating folate, vitamin B-12, and homocysteine concentrations in early pregnancy and in cord blood with cardiometabolic measurements in children aged 10 y.

| Characteristic                | Systolic blood pressure (n = 4295) | Diastolic blood pressure (n = 4295) | Glucose (n = 3092) | Total cholesterol (n = 3092) | HDL cholesterol (n = 3092) |
|------------------------------|------------------------------------|------------------------------------|-------------------|-----------------------------|---------------------------|
| Heart rate (n = 4237)        |                                    |                                    |                   |                             |                           |
| Maternal early pregnancy²    |                                    |                                    |                   |                             |                           |
| Folate,³ SDS                 | 0.02 (−0.02, 0.05)                 | −0.06 (−0.10, −0.03)**             | −0.03 (−0.06, 0.01) | 0.00 (−0.04, 0.05)          | 0.02 (−0.02, 0.06)         | 0.01 (−0.03, 0.06)         |
| ≥8 nmol/L                    | Reference                          | Reference                          | Reference         | Reference                   | Reference                 | Reference                 |
| <8 nmol/L                    | 0.02 (−0.03, 0.13)                 | 0.17 (0.06, 0.28)**                | 0.01 (−0.10 0.12) | 0.00 (−0.13, 0.13)          | −0.07 (−0.20, 0.07)        | −0.09 (−0.22, 0.04)        |
| Total B-12,⁴ SDS             | 0.01 (−0.03, 0.04)                 | 0.01 (−0.03, 0.04)                | 0.01 (−0.02, 0.05) | −0.06 (−0.10, −0.02)**      | 0.03 (−0.01, 0.08)         | 0.04 (0.00, 0.08)*         |
| ≥145 pmol/L                  | Reference                          | Reference                          | Reference         | Reference                   | Reference                 | Reference                 |
| <145 pmol/L                  | 0.09 (0.02, 0.16)**                | 0.03 (−0.04, 0.10)                | 0.01 (−0.06, 0.09) | 0.10 (0.01, 0.18)*          | −0.05 (−0.13, 0.04)        | −0.03 (−0.11, 0.06)        |
| Active B-12, SDS             | −0.03 (−0.07, 0.01)                | −0.03 (−0.07, 0.01)               | −0.05 (−0.09, −0.01)* | −0.01 (−0.06, 0.04)         | −0.01 (−0.06, 0.04)        | 0.02 (0.03, 0.06)          |
| Homocysteine, SDS            | −0.02 (−0.05, 0.01)                | 0.03 (−0.01, 0.06)                | −0.01 (−0.04, 0.03) | −0.01 (−0.04, 0.03)         | −0.03 (−0.07, 0.01)        | 0.01 (−0.03, 0.05)         |
| Folic acid supplement use    |                                    |                                    |                   |                             |                           |                           |
| No                           |                                    |                                    |                   |                             |                           |                           |
| From early pregnancy         | −0.05 (−0.17, 0.06)                | −0.11 (−0.23, 0.00)               | −0.01 (−0.12, 0.11) | 0.03 (−0.11, 0.17)          | 0.05 (−0.08, 0.19)         | 0.10 (−0.03, 0.23)         |
| From preconception           | 0.02 (−0.09, 0.13)                 | −0.19 (−0.30, −0.08)**            | −0.05 (−0.17, 0.07) | 0.01 (−0.13, 0.14)          | 0.04 (−0.09, 0.18)         | 0.18 (0.04, 0.31)**        |
| Cord blood²                  |                                    |                                    |                   |                             |                           |                           |
| Folate, SDS                  | −0.02 (−0.05, 0.02)                | −0.04 (−0.07, 0.00)               | −0.01 (−0.05, 0.03) | 0.01 (−0.04, 0.05)          | 0.01 (−0.04, 0.06)         | −0.01 (−0.05, 0.04)        |
| Total B-12, SDS              | −0.01 (−0.05, 0.02)                | 0.00 (−0.03, 0.04)                | 0.03 (−0.01, 0.06) | −0.04 (−0.08, 0.01)         | 0.04 (−0.01, 0.08)         | 0.04 (0.00, 0.08)          |
| Active B-12, SDS             | −0.04 (−0.08, −0.01)*              | 0.01 (−0.03, 0.04)                | 0.03 (−0.04, 0.07) | −0.05 (−0.1, −0.01)*        | 0.02 (−0.02, 0.07)         | 0.05 (0.00, 0.09)*         |
| Homocysteine, SDS            | 0.03 (−0.01, 0.06)                 | 0.02 (−0.02, 0.06)                | −0.02 (−0.06, 0.01) | 0.05 (0.01, 0.10)*          | −0.03 (−0.07, 0.02)        | −0.03 (−0.08, 0.01)        |

¹The main models were adjusted for child sex, gestational age at blood sampling, child age at outcome, maternal confounders (parity, age, education, prepregnancy BMI, smoking, alcohol consumption), and child ethnicity. Folate and homocysteine were measured in plasma and total and active B-12 were measured in serum. *P < 0.05. **P < 0.01. SDS, standard deviation score.

²For early pregnancy, active B-12 and homocysteine, and cord blood folate, total and active B-12 and homocysteine, the distribution of participants after dichotomization was deemed too uneven for meaningful analyses.

³Plasma folate ≥ 8 nmol/L: n = 3254; plasma folate < 8 nmol/L: n = 378.

⁴Serum total B-12 ≥ 45 pmol/L: n = 2001; serum total B-12 < 145 pmol/L: n = 1170.
The associations of extremely imbalanced maternal circulating folate/vitamin B-12 status with childhood cardiometabolic outcomes need further study.

Conclusions

Our results suggest that higher plasma folate concentrations in early pregnancy are associated with a more favorable body fat distribution and lower risk of obesity and clustering of cardiometabolic risk factors in children aged 10 y. We observed no consistent associations of cord blood folate, vitamin B-12, and homocysteine concentrations with cardiometabolic outcomes at age 10 y. Imbalanced maternal circulating high folate and low vitamin B-12 status may be associated with higher offspring glucose concentrations. The causality and underlying mechanisms for these associations need to be further studied.

Acknowledgments

The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam; the Municipal Health Service Rotterdam area, Rotterdam; the Rotterdam Homecare Foundation, Rotterdam; and the Stichting Trombosiedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We gratefully acknowledge the contribution of children and parents, general practitioners, hospitals, midwives, and pharmacies in Rotterdam.

The authors’ contributions were as follows—VWVJ: was responsible for conceptualization of this study; GSM: analyzed the data and wrote the original draft of the manuscript under the supervision of VWVJ; GSM, VWVJ, JFF, SGH, SS, and MLG: interpreted the data; JFF, SGH, SS, and MLG: were major contributors; and all authors: read and approved the final manuscript.

References

1. Barker DJP. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006;49:270–83.
2. Sinclair KD, Gi A, Singh R, Gardner DS, Sebastian S, Bispham J, Thurston A, Huntley JF, Rees WD, Maloney CA, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci 2007;104:19351–6.
3. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449–54.
4. Miliku K, Mesu A, Franco OH, Hofman A, Steegers EAP, Jaddoe VDW. Maternal and fetal folate, vitamin B12 and homocysteine concentrations and childhood kidney outcomes. Am J Kidney Dis 2017;69:521–30.
5. Sukumar N, Saravanan P. Investigating vitamin B12 deficiency. BMJ 2019;365:l1865.
6. Dominguez-Salas P, Cox SE, Prentice AM, Hennig JB, Moore ES. Maternal nutritional status, C1 metabolism and offspring DNA methylation: a review of current evidence in human subjects. Proc Nutr Soc 2012;71:154–65.
7. Visentin CE, Masih SP, Plumtree L, Schroder TH, Sohn KJ, Ly A, Lausman AY, Berger H, Croxford R, Lamers Y, et al. Low serum vitamin B12 concentrations are prevalent in a cohort of pregnant Canadian women. J Nutr 2016;146:1035–42.
8. Cikot RJ, Steegers-Theunissen RP, Thomas CM, de Boo TM, Merkus HM, Steegers EA. Longitudinal vitamin and homocysteine levels in normal pregnancy. Br J Nutr 2001;85:49–58.
9. Rogers LM, Cordero AM, Pfeiffer CM, Hausman DB, Tsang BL, De-Regil LM, Rosenthal J, Razzaghi H, Wang G, Hu FB, Mistry KB, Zhang C, Ren F, Huo Y, Paige D, Bartell T, Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L. Homocysteine and reclassification of cardiovascular risk: findings from the ABCD multi-ethnic birth cohort. BJOG 2016;123:384–92.
10. World Health Organization. Integrated management of pregnancy and childbirth: standards for maternal and neonatal care. Geneva (Switzerland): WHO; 2007.
11. Cordero AM, Crider KS, Rogers LM, Cannon MJ, Berry RJ. Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines. MMWR Morb Mortal Wkly Rep 2015;64:421–3.
12. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217–46.
13. Eckel RH, Cornier MA. Update on the NCEP ATP-III emerging cardiometabolic risk factors. BMC Med 2014;12:115.
14. McCully KS. Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol 2015;6:471–505.
15. Veeranna V, Zalawadiya SK, Niraj A, Padhian J, Ference B, Burack RC, Jacob S, Alonso L. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011;58:1025–33.
16. Krikke GG, Grooten IJ, Vrijkotte TGM, van Eijsden M, Roseboom J, Thurston A, Huntley JF, Rees WD, Maloney CA, et al. Global folate status in women of reproductive age: a systematic review with emphasis on methodological issues. Ann N Y Acad Sci 2018;1431:35–57.
17. De-Regil LM, Rosenthal J, Razzaghi H, Wang G, Hu FB, Mistry KB, Zhang C, Ren F, Huo Y, Paige D, Bartell T, Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, Jacob S, Afonso L. Homocysteine and reclassification of cardiovascular risk: findings from the ABCD multi-ethnic birth cohort. BJOG 2016;123:384–92.
18. Wang G, Hu FB, Mistry KB, Zhang C, Ren F, Huo Y, Paige D, Bartell T, Hong X, Caruso D, et al. Association between maternal prepregnancy body mass index and plasma folate concentrations with child metabolic health. JAMA Pediatr 2016;170(6):e160845.
19. Bergen NE, Jaddoe VW, Timmermans S, Hofman A, Lindemans J, Russcher H, Raat H, Steegers-Theunissen RP, Steegers EA. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study. BJOG 2012;119:739–51.

−− OR (95% CI for clustering cardiovascular risk factors (n = 4401)

TABLE 5  Associations of circulating folate, vitamin B-12, and homocysteine concentrations in early pregnancy and in cord blood with the risk of overweight/obesity and clustering at age 10 y

| Characteristic | OR (95% CI) for overweight/obesity (n = 4123) | OR (95% CI) for clustering cardiovascular risk factors (n = 4401) |
|---------------|---------------------------------------------|---------------------------------------------------------------|
| Maternal early pregnancy |                                           |                                                               |
| Folate, SDS | 0.87 (0.76, 0.96)** | 0.79 (0.68, 0.91)** |
| Total B-12, SDS | 0.99 (0.89, 1.10) | 0.92 (0.80, 1.05) |
| Active B-12, SDS | 0.99 (0.88, 1.10) | 0.92 (0.79, 1.06) |
| Homocysteine, SDS | 1.02 (0.93, 1.12) | 1.04 (0.93, 1.16) |
| Cord blood |                                           |                                                               |
| Folate, SDS | 0.98 (0.87, 1.09) | 1.00 (0.86, 1.15) |
| Total B-12, SDS | 0.99 (0.89, 1.10) | 0.92 (0.80, 1.07) |
| Active B-12, SDS | 1.10 (0.91, 1.12) | 0.90 (0.78, 1.04) |
| Homocysteine, SDS | 1.00 (0.90, 1.11) | 1.10 (0.97, 1.25) |

1 Associations are based on the main models with adjustment for child sex; gestational age at blood sampling; child age at outcome; maternal confounders (parity, age, education, prepregnancy BMI, smoking, alcohol consumption); and child ethnicity. Sensitivity analysis among mother–child pairs from Dutch ethnicity resulted in similar results (data not shown). Folate and homocysteine were measured in plasma and total and active B-12 were measured in serum. **P < 0.01. SDS, standard deviation score.
2 Reference group: children with normal weight. Overweight and obesity were defined based on the International Obesity Task Force cutoffs and were present in 75th percentile of our study population. Cardiovascular clustering was calculated in the subgroup of 4401 children with complete cardiovascular outcomes and present in n = 391 children.

OR (95% CI) for clustering cardiovascular risk factors (n = 4401)
19. Timmermans S, Jaddoe VW, Hofman A, Steegers-Theunissen RP, Steegers EA. Periconception folic acid supplementation, fetal growth and the risks of low birth weight and preterm birth: the Generation R Study. Br J Nutr 2009;102:777–85.

20. Timmermans S, Jaddoe VWV, Silva LM, Hofman A, Raat H, Steegers-Theunissen RP, Steegers EA. Folic acid is positively associated with uteroplacental vascular resistance: the Generation R study. Nutr Metab Cardiovasc Dis 2011;21:54–61.

21. van den Hil LC, Taal RH, de Jonge LL, Heppe DH, Steegers EA, Hofman A, van der Heijden AJ, Jaddoe VW. Maternal first-trimester dietary intake and childhood blood pressure: the Generation R Study. Br J Nutr 2013;110:1454–64.

22. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, Bhat DS, Naik SS, Coyaji KJ, Joglekar CV, et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia 2007;51:29–38.

23. Kooijman MN, Kruithof CJ, Van Duijn CM, Duijts L, Franco OH, de Zendoorn MH, de Jongste JC, Klaver CC, van der Lugt A, Mackenbach JP, et al. The Generation R Study: design and cohort update 2017. Eur J Epidemiol 2016;31:1243–64.

24. de Benoist B. Conclusions of a WHO technical consultation on folate and vitamin B12 deficiencies. Food Nutr Bull 2008;29(2 Suppl 1):S238–S44.

25. Heil SG, de Jonge R, de Rotte MC, van Wijnen M, Heiner-Rothe K, de Jonge P, et al. Selection of a common genetic variation associated with folate metabolism in normal pregnancy and in gestational diabetes. Diabetologia 2015;58:110–21.

26. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index measurements in 1996–7 compared with 1980. Arch Dis Child 2000;82:107–12.

27. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240–3.

28. Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, Ergun DL. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring) 2012;20:1313–8. DOI: 10.1038/oby.2011.393.

29. Santos S, Momnerau C, Felix JF, Duijts L, Gaillard R, Jaddoe VWV. Maternal body mass index, gestational weight gain, and childhood abdominal, pericardial, and liver fat assessed by magnetic resonance imaging. Int J Obes 2019;43:581–93.

30. Wong SN, Tsung Hung Y, Leung LC. Validation of three oscillometric blood pressure devices against auscultatory mercury sphygmomanometer in children. Blood Press Monit 2006;11:281–91.

31. Onyenekwu CP, Hoffmann M, Smit A, Mathsa TE, Erasmus RT. Comparison of LDL-cholesterol estimate using the Friedewald formula and the newly proposed de Cordova formula with a directly measured LDL-cholesterol in a healthy South African population. Ann Clin Biochem 2014;51:672–9.

32. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, Mietus-Snyder ML. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009;119:628–47.

33. Jaddoe VWV, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First trimester fetal growth restriction and cardiovascular risk factors in school age children: population based cohort study. BMJ 2014;348:g114.

34. Statistics Netherlands. Standrad onderwijsindeling 2003. (Standardised classification of educational level). Voorburg/Heerlen: Statistics Netherlands; 2004.

35. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr 1991;80:756–62.

36. Statistics Netherlands. Immigrants in the Netherlands 2004, (Allochtonen in Nederland 2004). Haag/Heerlen: Statistics Netherlands; 2004.

37. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.

38. Braun KVE, Voortman T, Kiefte-de Jong JC, Jaddoe VWV, Hofman A, Franco OH, van den Hooven EH. Dietary intakes of folic acid and methionine in early childhood are associated with body composition at school age. J Nutr 2015;145:2123–9.

39. Krishnaveni GV, Veena SR, Karat SC, Yajnik CS, Fall CHD. Association between maternal folate concentrations during pregnancy and insulin resistance in Indian children. Diabetologia 2014;57:110–21.

40. Adaikalakoteswari A, Vatish M, Lawson A, Wood C, Sivakumar K, McMerran PG, Webster C, Anderson N, Yajnik CS, Tripathi G, et al. Low maternal vitamin B12 status is associated with lower cord blood HDL cholesterol in white Caucasians living in the UK. Nutrients 2015;7:2401–14.

41. Wang H, Mueller NT, Li J, Sun N, Hoo Y, Ren F, Wang X. Association of maternal plasma folate and cardiometabolic risk factors in pregnancy with elevated blood pressure of offspring in childhood. Am J Hypertens 2017;30:532–40.

42. Di Cianni G, Miccoli R, Volpe L, Lencioni C, De Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab Res Rev 2003;19:259–70.

43. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764–79.

44. Silva CCV, Vehmeijer FOL, El Marroun H, Felix JF, Jaddoe VWV, Santos S. Maternal psychological distress during pregnancy and insulin resistance in Indian children. Diabetologia 2014;57:110–21.

45. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015;14:6.

46. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002;7:227–39.

47. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–81.